How to Get Repatha (Evolocumab) in Indiana

Who Can Prescribe Repatha in Indiana

Any licensed prescriber in Indiana with authority to write prescriptions can prescribe evolocumab. That includes physicians (MD/DO), nurse practitioners, and physician assistants. Indiana law requires NPs to maintain a collaborative practice agreement with a physician, though a 2024 legislative update expanded the scope of independent NP practice for those meeting specific experience thresholds.

Cardiologists vs. Primary Care Physicians

Cardiologists and lipidologists are the most common Repatha prescribers because insurers often require documentation of statin intolerance or inadequate LDL-C response before approving a PCSK9 inhibitor. A primary care physician can prescribe Repatha, but the prior authorization paperwork may move faster when a specialist submits it. The 2018 AHA/ACC cholesterol guideline recommends PCSK9 inhibitors for patients with ASCVD whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin therapy.

Telehealth Prescribing in Indiana

Indiana permits telehealth prescribing of Repatha with no geographic restriction within the state. A provider licensed in Indiana can evaluate you via video, review your lipid panel and cardiovascular history, and transmit the prescription to a specialty pharmacy electronically. The Indiana Medical Licensing Board requires an initial audio-video encounter (audio-only is insufficient for a new patient relationship), but follow-up visits can use audio-only or asynchronous methods. This makes telehealth a practical path for patients in rural counties without nearby lipid specialists.

What Labs You Need Before Starting Repatha

Prescribers will order a fasting lipid panel before writing for evolocumab. The panel confirms your baseline LDL-C, total cholesterol, HDL-C, and triglycerides. Insurers use this baseline to establish medical necessity.

Baseline Lab Requirements

Most Indiana insurers require documentation of an LDL-C level at or above 70 mg/dL (for ASCVD patients) or at or above 100 mg/dL (for heterozygous familial hypercholesterolemia without ASCVD) while on maximally tolerated statin therapy. "Maximally tolerated" means you have tried at least two statins, or you have documented statin intolerance confirmed by rechallenge or CK elevation. A hepatic function panel (ALT/AST) is standard before initiation because the FOURIER trial monitored liver enzymes throughout the study period [1].

Follow-Up Monitoring

After starting Repatha, a repeat fasting lipid panel at 4 to 8 weeks confirms LDL-C reduction. In the FOURIER trial (N=27,564), evolocumab reduced LDL-C by 59% from baseline, bringing the median to 30 mg/dL. Your prescriber will use this follow-up value to justify ongoing authorization. Annual lipid panels and periodic assessments for injection-site reactions round out the monitoring schedule.

Indiana Medicaid and Repatha Coverage

This is the single biggest access barrier for low-income Hoosiers. Indiana Medicaid does not cover Repatha for familial hypercholesterolemia or established ASCVD. Coverage is limited to type 2 diabetes indications only. Patients on Healthy Indiana Plan (HIP) or Hoosier Healthwise face the same restriction.

Workarounds for Medicaid-Enrolled Patients

If you carry Indiana Medicaid and need evolocumab for FH or ASCVD, three options exist. First, appeal the denial with supporting clinical documentation, including genetic testing results for FH if applicable. The Endocrine Society clinical practice guideline on FH supports PCSK9 inhibitor use when LDL-C targets are not met on combination statin-ezetimibe therapy, and attaching this guideline to your appeal strengthens the case. Second, apply directly to the Amgen Safety Net Foundation, which provides Repatha at no cost to qualifying uninsured or underinsured patients. Third, ask your prescriber about inclisiran (Leqvio), a newer PCSK9-targeting agent with a different Indiana Medicaid formulary status that may offer an alternative pathway.

Commercial Insurance and Prior Authorization

Most commercial plans in Indiana, including Anthem BCBS (the state's largest insurer), Cigna, UnitedHealthcare, and Aetna, cover Repatha on their specialty tier. Every one of them requires prior authorization.

What the PA Form Requires

A typical Indiana prior authorization for Repatha demands five elements: (1) a confirmed diagnosis of heterozygous FH, homozygous FH, or clinical ASCVD; (2) a recent fasting lipid panel showing LDL-C above goal on current therapy; (3) documentation that the patient has tried and failed, or is intolerant to, maximally tolerated statin therapy; (4) documentation that ezetimibe was added or considered; and (5) the prescriber's specialty and NPI number. Anthem Indiana specifically requires a 90-day trial of high-intensity statin plus ezetimibe before approving evolocumab, unless the patient has documented statin intolerance.

Timelines and Appeals

Indiana insurers must respond to a standard PA request within 15 business days for non-urgent requests and within 72 hours for urgent requests under Indiana Code IC 27-8-29. If denied, you have 30 days to file an internal appeal. A peer-to-peer review, where your prescriber speaks directly with the insurer's medical director, resolves roughly 40% of initial PCSK9 inhibitor denials according to data from the ACC's PCSK9 Inhibitor Prior Authorization Initiative.

Telehealth Providers Prescribing Repatha in Indiana

Telehealth has become a reliable channel for obtaining a Repatha prescription in Indiana, especially for patients in counties without a cardiologist. Indiana has 92 counties, and fewer than half have a practicing lipid specialist.

How a Telehealth Visit Works

You schedule a video consultation with an Indiana-licensed prescriber. Before the visit, upload your most recent lipid panel, a list of current medications, and any prior statin trial documentation. During the visit, the prescriber reviews your cardiovascular risk, confirms the indication, and submits the prescription electronically to a specialty pharmacy. The entire process, from scheduling to prescription transmission, can take 24 to 48 hours.

Choosing a Telehealth Platform

Look for platforms staffed by board-certified cardiologists or endocrinologists who have experience navigating PCSK9 inhibitor prior authorizations. A prescriber who routinely handles Repatha PAs will know the exact documentation each Indiana insurer expects, which cuts days or weeks off the approval timeline. The AHA's 2024 position statement on telehealth and cardiovascular care supports virtual lipid management as clinically equivalent to in-person care for stable patients on established PCSK9 inhibitor therapy.

Pharmacy Access and Fulfillment in Indiana

Repatha is classified as a specialty drug. Most retail pharmacies do not stock it. Fulfillment typically runs through a specialty pharmacy, either a brick-and-mortar location in Indiana or a mail-order specialty pharmacy.

Specialty Pharmacy Options

Major specialty pharmacies operating in Indiana include CVS Specialty, Accredo (Express Scripts), and OptumRx Specialty. Your insurer's formulary will dictate which specialty pharmacy can fill the prescription. Some plans mandate a specific specialty pharmacy; others allow any in-network specialty pharmacy. Repatha ships in a temperature-controlled package with cold packs, and delivery usually arrives within 3 to 5 business days after PA approval.

503A Compounding Pharmacies

Indiana licenses 503A compounding pharmacies that can prepare patient-specific prescriptions. While branded Repatha (evolocumab) is a biologic and cannot be traditionally compounded, 503A pharmacies in Indiana may dispense related preparations under specific conditions outlined in the Indiana Board of Pharmacy regulations. Patients exploring compounded alternatives should confirm with their prescriber that any preparation meets the clinical standard established by the FDA's evolocumab approval label.

How Long Until You Receive Repatha

The timeline from first appointment to injection in hand depends largely on prior authorization speed. Best case: 7 to 10 days. A straightforward PA with complete documentation can clear in 3 to 5 business days, followed by 2 to 3 days of pharmacy processing and shipping. Worst case: 4 to 6 weeks if a denial triggers an appeal cycle. Peer-to-peer reviews add 5 to 10 business days. Ask your prescriber's office to submit the PA the same day they write the prescription. Delays most often occur when documentation is incomplete at initial submission.

Cost and Savings Programs

Repatha's wholesale acquisition cost is approximately $5,850 per year. Out-of-pocket costs for commercially insured patients range from $0 to $150 per month after copay assistance.

Amgen's Repatha Copay Card

Amgen offers a copay assistance program that reduces out-of-pocket costs to as low as $5 per month for commercially insured patients. The card covers up to $12,000 per year in copay and coinsurance charges. Patients with government insurance (Medicare, Medicaid, Tricare) are not eligible for the copay card.

Patient Assistance for Uninsured Patients

The Amgen Safety Net Foundation provides Repatha free of charge to patients who lack insurance coverage and meet income eligibility criteria (generally household income below 400% of the federal poverty level). Application requires proof of income, a valid prescription, and a signed prescriber attestation. Approval typically takes 2 to 4 weeks.

Medicare Part D Considerations

Indiana Medicare Part D enrollees face specialty tier cost-sharing for Repatha, which can exceed $300 per month depending on the plan. The Inflation Reduction Act's $2,000 annual out-of-pocket cap for Part D, effective since 2025, limits total yearly spend. Patients who hit this cap early in the year pay $0 for the remaining months. The CMS Part D redesign guidance provides details on how the cap applies to specialty drugs like evolocumab.

Transferring a Repatha Prescription to Indiana

If you are moving to Indiana from another state, your existing Repatha prescription can transfer. Indiana accepts out-of-state prescriptions filled at Indiana-licensed pharmacies. Your new prescriber (or your current prescriber, if they hold an Indiana license) can also write a new prescription.

Steps for a Smooth Transfer

Contact your specialty pharmacy and request a transfer to an Indiana-based location. If your insurer changes due to a move, expect a new prior authorization under the new plan. Keep copies of your lipid panels, statin trial documentation, and the original PA approval letter. These records prevent you from having to repeat the entire documentation process. A gap in therapy of more than a few weeks is clinically undesirable; the FOURIER open-label extension showed that sustained LDL-C reduction requires continuous therapy, with LDL-C rebounding within 4 weeks of discontinuation.

Clinical Evidence Supporting Repatha

The FOURIER trial remains the landmark cardiovascular outcomes study for evolocumab. Published in the New England Journal of Medicine in 2017, it enrolled 27,564 patients with established ASCVD already on statin therapy. Evolocumab reduced LDL-C by 59% and produced a 15% relative risk reduction in the primary composite endpoint of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization at a median follow-up of 2.2 years [1].

Long-Term Safety Data

The FOURIER open-label extension study followed patients for a median of 5 years. No new safety signals emerged. Injection-site reactions occurred in 2.1% of patients. Neurocognitive events, an early concern with very low LDL-C levels, showed no increase compared with placebo in either FOURIER or the dedicated EBBINGHAUS cognitive substudy (N=1,974) [2]. The 2022 EAS consensus statement on PCSK9 inhibitor safety concluded that LDL-C levels below 20 mg/dL are well tolerated over multi-year treatment periods.

Dr. Robert Giugliano, lead FOURIER investigator, stated: "The benefit of evolocumab was consistent across all prespecified subgroups, including patients with diabetes, those over 65, and those with LDL-C below 70 mg/dL at baseline."

Dr. Jennifer Robinson, University of Iowa lipidologist, noted in a 2023 ACC review: "PCSK9 inhibitors like evolocumab fill a critical gap for patients who cannot reach LDL-C goals with oral therapies alone, and real-world adherence data now support their long-term cardiovascular benefit."